MX2009003974A - N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion. - Google Patents

N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion.

Info

Publication number
MX2009003974A
MX2009003974A MX2009003974A MX2009003974A MX2009003974A MX 2009003974 A MX2009003974 A MX 2009003974A MX 2009003974 A MX2009003974 A MX 2009003974A MX 2009003974 A MX2009003974 A MX 2009003974A MX 2009003974 A MX2009003974 A MX 2009003974A
Authority
MX
Mexico
Prior art keywords
methyl
ylidene
quinolin
thiazol
benzamide
Prior art date
Application number
MX2009003974A
Other languages
English (en)
Spanish (es)
Inventor
Cathy Dantzman
Glen Ernst
Thomas Hudzik
Khanh Bui
Valerie Hoesch
Megan Murphy King
Jie Liu
Jingbo Yan
Original Assignee
Aztrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aztrazeneca Ab filed Critical Aztrazeneca Ab
Publication of MX2009003974A publication Critical patent/MX2009003974A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MX2009003974A 2006-10-20 2007-10-19 N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion. MX2009003974A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86232706P 2006-10-20 2006-10-20
PCT/SE2007/000924 WO2008048171A1 (en) 2006-10-20 2007-10-19 N- (2 -hydroxyethyl) -n-methyl- 4- (quinolin- 8-yl (1- (thiazol-4- ylmethyl) piperidin- 4 -ylidene) methyl) benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression.

Publications (1)

Publication Number Publication Date
MX2009003974A true MX2009003974A (es) 2009-04-27

Family

ID=39314285

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003974A MX2009003974A (es) 2006-10-20 2007-10-19 N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion.

Country Status (32)

Country Link
US (2) US7659286B2 (enExample)
EP (1) EP2079735B1 (enExample)
JP (1) JP4668346B2 (enExample)
KR (1) KR20090065534A (enExample)
CN (1) CN101528739B (enExample)
AR (1) AR063345A1 (enExample)
AT (1) ATE543818T1 (enExample)
AU (2) AU2007313515B2 (enExample)
BR (1) BRPI0717631A2 (enExample)
CA (1) CA2667041C (enExample)
CL (1) CL2007003009A1 (enExample)
CO (1) CO6180450A2 (enExample)
CY (1) CY1112718T1 (enExample)
DK (1) DK2079735T3 (enExample)
ES (1) ES2379519T3 (enExample)
HR (1) HRP20120344T1 (enExample)
IL (1) IL197876A0 (enExample)
MX (1) MX2009003974A (enExample)
MY (1) MY148880A (enExample)
NO (1) NO20091969L (enExample)
NZ (1) NZ577060A (enExample)
PE (2) PE20080892A1 (enExample)
PL (1) PL2079735T3 (enExample)
PT (1) PT2079735E (enExample)
RS (1) RS52260B (enExample)
RU (1) RU2454414C2 (enExample)
SA (1) SA07280549B1 (enExample)
SI (1) SI2079735T1 (enExample)
TW (1) TW200826939A (enExample)
UA (1) UA97648C2 (enExample)
UY (1) UY30652A1 (enExample)
WO (1) WO2008048171A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641757A1 (en) * 2003-05-16 2006-04-05 AstraZeneca AB Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
BRPI0912756A2 (pt) * 2008-05-20 2015-10-13 Astrazeneca Ab método para tratar transtorno depressivo maior ansioso em um animal de sangue quente, uso de um composto, composto, e, composição farmacêutica
CN101906078B (zh) * 2009-06-08 2012-02-01 上海威智医药科技有限公司 噻唑衍生物的合成方法
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
WO2016099393A1 (en) * 2014-12-19 2016-06-23 Pharmnovo Ab Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
EP3853435B1 (en) 2018-09-21 2024-08-21 Garland Industries, Inc. Helical hardbanding

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898339A (en) * 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) * 1983-07-27 1986-04-08 Janssen Pharmaceutica, N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
TW548271B (en) * 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
AU2009799A (en) * 1997-12-24 1999-07-19 Ortho-Mcneil Pharmaceutical, Inc. 4-(aryl(piperidin-4-yl)) aminobenzamides which bind to the delta-opioid receptor
US6492375B2 (en) * 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
SE9904673D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
AU784848B2 (en) 1999-12-20 2006-07-06 Zalicus Pharmaceuticals Ltd. Partially saturated calcium channel blockers
CN1426411A (zh) * 2000-03-03 2003-06-25 奥索-麦克尼尔药品公司 3－(二芳基亚甲基)－8－氮杂双环[3.2.1]辛烷衍生物
SE0001208D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101768D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
US20040204404A1 (en) * 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
SE0300105D0 (sv) * 2003-01-16 2003-01-16 Astrazeneca Ab Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0301444D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301442D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
EP1641757A1 (en) * 2003-05-16 2006-04-05 AstraZeneca AB Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301445D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301441D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0400025D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
MY148880A (en) * 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Also Published As

Publication number Publication date
CY1112718T1 (el) 2016-02-10
TW200826939A (en) 2008-07-01
EP2079735A4 (en) 2010-12-29
EP2079735A1 (en) 2009-07-22
CL2007003009A1 (es) 2008-06-06
ES2379519T3 (es) 2012-04-26
EP2079735B1 (en) 2012-02-01
RU2009111337A (ru) 2010-11-27
HK1131556A1 (en) 2010-01-29
IL197876A0 (en) 2009-12-24
KR20090065534A (ko) 2009-06-22
CA2667041C (en) 2011-09-06
ATE543818T1 (de) 2012-02-15
CA2667041A1 (en) 2008-04-24
RU2454414C2 (ru) 2012-06-27
AR063345A1 (es) 2009-01-21
SA07280549B1 (ar) 2010-09-29
AU2007313515A1 (en) 2008-04-24
PL2079735T3 (pl) 2012-07-31
CN101528739B (zh) 2011-11-30
RS52260B (sr) 2012-10-31
PE20140634A1 (es) 2014-06-19
JP2010506910A (ja) 2010-03-04
PT2079735E (pt) 2012-05-07
UY30652A1 (es) 2008-05-31
US20080182875A1 (en) 2008-07-31
MY148880A (en) 2013-06-14
US20100160374A1 (en) 2010-06-24
BRPI0717631A2 (pt) 2013-10-29
WO2008048171A1 (en) 2008-04-24
SI2079735T1 (sl) 2012-05-31
CO6180450A2 (es) 2010-07-19
UA97648C2 (ru) 2012-03-12
NZ577060A (en) 2011-01-28
US7659286B2 (en) 2010-02-09
HRP20120344T1 (hr) 2012-05-31
NO20091969L (no) 2009-05-20
AU2010226996A1 (en) 2010-10-28
JP4668346B2 (ja) 2011-04-13
DK2079735T3 (da) 2012-05-21
PE20080892A1 (es) 2008-09-11
US7977355B2 (en) 2011-07-12
AU2007313515B2 (en) 2010-11-25
CN101528739A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
JO3021B1 (ar) احادي هيدرات 4-[ 4-{[4- كلورو - 3- (ثلاثي فلورو ميثيل) فينيل ] كربامويل} امينو] -3- فلورو فينوكسي] -n- ميثيل بيريدين -2- كربوكساميد
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
ZA200804030B (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof
GEP20115357B (en) Amine derivatives
MX2009003974A (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion.
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
MX2011011764A (es) Compuestos de carboxamida y su uso como inhibidores de calpaina.
NO20091052L (no) Diaryleterderivater og anvendelser derav
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
UA96277C2 (en) Benzimidazole derivatives
SE0402284D0 (sv) New heterocyclic amides
GEP20156225B (en) Therapeutic agent for anxiety disorders
PL1853232T3 (pl) Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
MY145139A (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
IL186373A0 (en) Use of agomelatine for obtaining medicaments used for treating bipolar disorders
DK1778622T3 (da) Para-alkyl-substituerede N-(4-hydroxy-3-methoxy-benzyl)-kanelsyreamider og anvendelse deraf til fremstilling af lægemidler
MX2008007195A (es) Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas.
DK1776366T3 (da) Immunomodulerende oxopyrazolocinnoliner som CD80-inhibitorer
SG143202A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of periventricular leukomalacia
MX2007013306A (es) Nuevas tiazolidinonas sin nitrogeno basico, su produccion y su uso como agentes farmaceuticos.

Legal Events

Date Code Title Description
FG Grant or registration